Ignite Creation Date:
2025-12-25 @ 2:34 AM
Ignite Modification Date:
2025-12-30 @ 9:59 AM
Study NCT ID:
NCT06201234
Status:
RECRUITING
Last Update Posted:
2025-12-01
First Post:
2023-12-07
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer
Sponsor:
GBG Forschungs GmbH
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-12-13
Start Date Type:
ACTUAL
Primary Completion Date:
2028-12-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2023-12-07
First Submit QC Date:
None
Study First Post Date:
2024-01-11
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-24
Last Update Post Date:
2025-12-01
Last Update Post Date Type:
ESTIMATED